Arch Biopartners Closes Private Placement
Analysis based on 9 articles · First reported Apr 02, 2026 · Last updated Apr 02, 2026
The private placement by Arch Biopartners provides additional capital for its operations and drug development, which could positively impact its stock price and future prospects. The transaction is subject to regulatory approval from the TSX Venture Exchange, which is a standard procedure for such offerings.
Arch Biopartners has successfully closed a non-brokered private placement offering, raising $600,000 CAD through the issuance of 1,000,000 common shares at $0.60 per share. The proceeds are earmarked for general working capital and operating expenses not covered by existing human trial funding grants. An officer of Arch Biopartners participated in the offering, acquiring 81,667 common shares, which is considered a related party transaction but is exempt from certain regulatory requirements. The offering is contingent on final approval from the TSX Venture Exchange. Arch Biopartners is a therapeutic biotech company focused on developing drugs for acute kidney injury and chronic kidney disease, with lead programs in Phase II trials.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard